Pfizer raises 2022 earnings guidance, beats third-quarter expectations

Pfizer raises 2022 earnings guidance, beats third-quarter expectations


Vials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.

Rodrigo Garrido | Reuters

Pfizer on Tuesday raised its 2022 earnings guidance after booking a strong third quarter that beat Wall Street expectations.

Pfizer now expects earnings per share of $6.40 to $6.50 for the year, up from its previous forecast of $6.30 to $6.45. The pharmaceutical company also raised the lower end of its sales guidance and now expects revenues of $99.5 billion to $102 billion for the year.

Pfizer raised its full year sales guidance for its Covid-19 vaccine to $34 billion this year, up $2 billion from the company’s previous expectations. The company is maintaining its revenue expectations of $22 billion for the antiviral pill Paxlovid.

Its shares rose by about 4% in premarket trading.

Here’s how the company performed compared with what Wall Street expected for the third quarter, based on analysts’ average estimates compiled by Refinitiv:

  • Adjusted EPS: $1.78 per share vs. $1.39 expected
  • Revenues: $22.6 billion vs. $21 billion expected

Pfizer’s sold $4.4 billion of its Covid vaccine worldwide in the quarter, a decrease of 66% compared to the same period last year. It sold $7.5 billion of the Paxlovid treatment during the quarter that ended Sept. 30.

Pfizer booked net income of $8.6 billion for the third quarter, a 6% increase over the same quarter last year.

Pfizer CEO Albert Bourla indicated that company is looking beyond the Covid pandemic which has led to record windfalls for the pharmaceutical giant.

Bourla said in a statement that Pfizer plans to launch 19 new products or new uses for existing drugs in the next 18 months. The company, for example, reported positive clinical trial data Tuesday for its maternal RSV vaccine that protects newborns.

The RSV vaccine is administered as a single dose to the mother in the late second or third trimester of her pregnancy. Pfizer’s data showed that in the first 90 days of the baby’s life, the vaccine was 81% effective at preventing severe lower respiratory tract illnesses that require hospitalization or assisted breathing.

This is breaking news. Please check back for updates.



Source

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots
Health

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, ACIP Executive Secretary, CDC, look on as people present their information to members of the Advisory Committee on Immunization Practices, as the U.S. Centers for Disease Control and Prevention’s (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025. Megan Varner […]

Read More
Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals
Health

Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals

An aerial view of Valley Health Hampshire Memorial Hospital on June 17, 2025 in Romney, W.V. Ricky Carioti | The Washington Post | Getty Images President Donald Trump’s “big, beautiful bill” would make sweeping changes to U.S. health care, leaving millions of vulnerable Americans without health insurance and threatening the hospitals and centers that provide […]

Read More
Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Health

Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and […]

Read More